Synageva Upsizes Again and Seeks $100M in Public Offering

Synageva BioPharma Corp. took advantage of a 2 percent increase in its stock price during the New Year and bumped up the number of shares to boost the size of its public offering by 25 percent, from approximately 1.7 million shares cited in a preliminary prospectus supplement filed Thursday with the SEC to 2.15 million shares at Thursday's closing price of $47.53.